Spots Global Cancer Trial Database for Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
Official Title: A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Study ID: NCT03088527
Interventions
Study Description
Brief Summary: The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.
Detailed Description: This is a first in humans study that is designed to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Yale Cancer Center, New Haven, Connecticut, United States
Cancer Center Protocol Office, Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact Details
Name: Sr. Director, Clinical Operations
Affiliation: Radius
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
